PET molecular imaging for pathophysiological visualization in Alzheimer’s disease

被引：0
作者：
Jing Wang
Chentao Jin
Jinyun Zhou
Rui Zhou
Mei Tian
Hyeon Jeong Lee
Hong Zhang
机构：
[1] The Second Affiliated Hospital of Zhejiang University School of Medicine,Department of Nuclear Medicine and PET Center
[2] Institute of Nuclear Medicine and Molecular Imaging of Zhejiang University,College of Biomedical Engineering and Instrument Science
[3] Key Laboratory of Medical Molecular Imaging of Zhejiang Province,Key Laboratory for Biomedical Engineering of Ministry of Education
[4] Zhejiang University,undefined
[5] Zhejiang University,undefined
来源：
European Journal of Nuclear Medicine and Molecular Imaging | 2023年 / 50卷
关键词：
Alzheimer’s disease; Positron emission tomography (PET); Molecular imaging;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Alzheimer’s disease (AD) is the most common dementia worldwide. The exact etiology of AD is unclear as yet, and no effective treatments are currently available, making AD a tremendous burden posed on the whole society. As AD is a multifaceted and heterogeneous disease, and most biomarkers are dynamic in the course of AD, a range of biomarkers should be established to evaluate the severity and prognosis. Positron emission tomography (PET) offers a great opportunity to visualize AD from diverse perspectives by using radiolabeled agents involved in various pathophysiological processes; PET imaging technique helps to explore the pathomechanisms of AD comprehensively and find out the most appropriate biomarker in each AD phase, leading to a better evaluation of the disease. In this review, we discuss the application of PET in the course of AD and summarized radiolabeled compounds with favorable imaging characteristics.
引用
收藏
页码：765 / 783
页数：18
相关论文
共 962 条
  • [1] Khachaturian ZS(1985)Diagnosis of Alzheimer’s disease Arch Neurol 42 1097-1105
  • [2] Grasset L(2016)Trends in dementia incidence: evolution over a 10-year period in France Alzheimers Dement 12 272-280
  • [3] Brayne C(2016)A two decade dementia incidence comparison from the Cognitive Function and Ageing Studies I and II Nat Commun 7 11398-532
  • [4] Joly P(2016)Incidence of dementia over three decades in the Framingham Heart Study N Engl J Med 374 523-124
  • [5] Jacqmin-Gadda H(2016)Dementia in western Europe: epidemiological evidence and implications for policy making Lancet Neurol 15 116-344
  • [6] Peres K(2010)Alzheimer’s disease N Engl J Med 362 329-106
  • [7] Foubert-Samier A(2016)Amyloid imaging: past, present and future perspectives Ageing Res Rev 30 95-269
  • [8] Matthews FE(2011)The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease Alzheimers Dement 7 263-629
  • [9] Stephan BC(2014)Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria Lancet Neurol 13 614-944
  • [10] Robinson L(1984)Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease Neurology 34 939-230
12345678910